$26.6598
0.8698[3.37%]
At close: May 22
$26.6598
0[0.00%]
After Hours: 5:38PM EDT
Mirum Pharmaceuticals
(NASDAQ:MIRM)Latest News for Mirum Pharmaceuticals Stock (NASDAQ:MIRM)
Mirum Pharmaceuticals Stock (NASDAQ: MIRM)
Categories: All
Monday, May 20, 2024
Friday, May 10, 2024
Thursday, May 09, 2024
- JMP Securities Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $66Benzinga Newsdesk - May 9, 2024, 2:39PM
- Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $38Benzinga Newsdesk - May 9, 2024, 1:45PM
- Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $40 Price TargetBenzinga Newsdesk - May 9, 2024, 10:25AM
- Analyst Ratings For Mirum PharmaceuticalsBenzinga Insights - May 9, 2024, 8:01AM
- HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $58 Price TargetBenzinga Newsdesk - May 9, 2024, 6:38AM
Wednesday, May 08, 2024
Tuesday, May 07, 2024
Wednesday, April 17, 2024
Tuesday, April 02, 2024
- HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Maintains $58 Price TargetBenzinga Newsdesk - Apr 2, 2024, 11:37AM
- Mirum Pharmaceuticals' LIVMARLI Receives Reimbursement Recommendation By Canada's CADTH For Patients With Cholestatic Pruritus In Alagille SyndromeBenzinga Newsdesk - Apr 2, 2024, 8:37AM
Thursday, March 28, 2024
Monday, March 18, 2024
Thursday, March 14, 2024
- FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion StrategyVandana Singh - Mar 14, 2024, 3:40PM
- Mirum Pharmaceuticals shares are trading higher after the company announced that the FDA approved LIVMARLI oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $45 to $58.Benzinga Newsdesk - Mar 14, 2024, 7:54AM
- HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $58Benzinga Newsdesk - Mar 14, 2024, 6:45AM
Wednesday, March 13, 2024
Monday, March 04, 2024
Thursday, February 29, 2024
- HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $45Benzinga Newsdesk - Feb 29, 2024, 3:07PM
- JMP Securities Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $69Benzinga Newsdesk - Feb 29, 2024, 2:25PM
- Critical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To KnowBenzinga Insights - Feb 29, 2024, 2:02PM
- Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $35 Price TargetBenzinga Newsdesk - Feb 29, 2024, 1:36PM
- Mirum Pharmaceutics Announces Hepatology Publishes Six-Year Data For Clinical Outcomes On Patients With Alagille Syndrome Treated With LIVMARLIBenzinga Newsdesk - Feb 29, 2024, 9:03AM
Wednesday, February 28, 2024
- Mirum Pharmaceuticals: Q4 Earnings InsightsBenzinga Insights - Feb 28, 2024, 4:40PM
- Mirum Pharmaceuticals Q4 2023 GAAP EPS $(0.66) Misses $(0.24) Estimate, Sales $69.55M Beat $67.76M EstimateBenzinga Newsdesk - Feb 28, 2024, 4:39PM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM
Tuesday, February 27, 2024
Tuesday, January 16, 2024
Thursday, January 11, 2024
Wednesday, January 10, 2024
Tuesday, December 19, 2023
- The Latest Analyst Ratings For Mirum PharmaceuticalsBenzinga Insights - Dec 19, 2023, 1:00PM
- Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For TuesdayAvi Kapoor - Dec 19, 2023, 7:30AM
- Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Lowers Price Target to $64Benzinga Newsdesk - Dec 19, 2023, 4:08AM
Monday, December 18, 2023
- HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $58Benzinga Newsdesk - Dec 18, 2023, 2:34PM
- Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Dec 18, 2023, 1:05PM
- Mirum Pharmaceuticals shares are trading lower after the company announced the Phase 2 EMBARK study for biliary atresia did not meet primary or secondary endpoints.Benzinga Newsdesk - Dec 18, 2023, 11:26AM
- Mirum Pharmaceuticals Announces Data From EMBARK Phase 2b Study for Biliary Atresia; Study Did Not Meet Primary Or Secondary EndpointsBenzinga Newsdesk - Dec 18, 2023, 8:33AM